source
- FDA launches Neuroscience Advancement and Innovation Nexus to boost brain disorder drug developmentThe U.S. Food and Drug Administration announced a new program called the Neuroscience Advancement and Innovation Nexus (NAIN) aimed at accelerating the development of medical products for brain and…
- Biohaven's ataxia drug resubmission accepted by FDA, shares surge 36%Biohaven’s experimental drug troriluzole, being developed for spinocerebellar ataxia, was previously rejected by the FDA because the agency questioned the design of the registrational trial. The co…